Preimplantation Genetic Testing Market Report 2025

This preimplantation genetic testing market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The preimplantation genetic testing market size has grown rapidly in recent years. It will grow from $0.83 billion in 2024 to $0.92 billion in 2025 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to increasing incidence of genetic disorders, growing awareness of genetic testing, increase in prenatal testing options, growing demand for personalized medicine, and increasing focus on preventive healthcare.

The preimplantation genetic testing market size is expected to see rapid growth in the next few years. It will grow to $1.41 billion in 2029 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be attributed to the rising number of fertility clinics, growth in genetic counseling services, growing prevalence of advanced maternal age, increasing availability of advanced genetic testing platforms, and expanding applications of PGT. Major trends in the forecast period include the adoption of advanced sequencing technologies, implementation of expanded genetic panels, development of non-invasive testing methods, advancements in embryo culture systems, and advancements in genetic editing technologies.

The growing number of in vitro fertilization (IVF) procedures is projected to drive the expansion of the preimplantation genetic testing market in the future. IVF involves fertilizing an egg with sperm outside the body to create an embryo, which is then implanted into the uterus. The increase in IVF procedures is fueled by advancements in reproductive technology, rising infertility rates, and greater public awareness. This surge in IVF practices is also leading to a higher demand for genetic screening of embryos before implantation, thereby benefiting the preimplantation genetic testing market. For example, the Society for Assisted Reproductive Technology, a U.S.-based organization, reported in April 2024 that 91,771 babies were born through IVF in 2022. Consequently, the rise in IVF procedures is contributing to the growth of the preimplantation genetic testing market.

Key players in the preimplantation genetic testing market are advancing next-generation sequencing (NGS) technologies to improve the accuracy, efficiency, and speed of genetic screening. NGS tools provide rapid, high-throughput analysis of DNA and RNA, offering detailed insights into genetic variations and gene expression, which enhances personalized medicine. For instance, in July 2023, Thermo Fisher Scientific, a US-based biotechnology firm, introduced the Ion ReproSeq PGT-A Kit and the Ion AmpliSeq Polyploidy Kit. These NGS tools are designed to improve IVF and ICSI research by streamlining workflows from sample processing to aneuploidy analysis using the ion torrent genexus integrated sequencer. This advancement enhances embryo screening and boosts success rates in assisted reproductive technologies.

In June 2022, Kindbody, a U.S.-based provider of fertility and wellness services, acquired the genomics company Phosphorus Labs for an undisclosed amount. This acquisition enables Kindbody to incorporate genetic testing capabilities into its fertility services, thereby improving patient care with personalized treatment plans. Phosphorus Labs specializes in preimplantation genetic testing in the U.S.

Major companies operating in the preimplantation genetic testing market are Thermo Fisher Scientific, Abbott Laboratories, Laboratory Corporation of America Holdings, Agilent Technologies Inc., Illumina Inc., Revvity Health Science Inc., CooperSurgical Inc., Natera Inc., Progyny Inc., Myriad Genetics Inc., Fulgent Genetics Inc., Invitae Corporation, Takara Bio Inc., MedGenome Labs Ltd., Genea Limited, Ovation Fertility, Juno Genetics Ltd, Invicta Genetics, Progenesis, Bioarray SL, PacGenomics, Reproductive Genetic Innovations LLC, SEQUENCE46 LLC.

North America was the largest region in the preimplantation genetic testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preimplantation genetic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the preimplantation genetic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Preimplantation genetic testing (PGT) is a procedure used to examine embryos for genetic abnormalities before they are implanted during in vitro fertilization (IVF). This testing aims to identify genetic issues to prevent certain inherited conditions, thus improving the chances of a successful pregnancy. PGT helps increase the likelihood of successful implantation, reduces the risk of miscarriage, and prevents genetic diseases.

The main types of preimplantation genetic testing are preimplantation genetic screening (PGS) and preimplantation genetic diagnosis (PGD). PGS involves analyzing embryos for chromosomal abnormalities before implantation. Products used in PGT include reagents and consumables, instruments, and software, and various technologies such as next-generation sequencing (NGS), polymerase chain reaction (PCR), and fluorescent in situ hybridization (FISH). These procedures are employed for applications including chromosomal abnormalities, aneuploidy screening, X-linked diseases, embryo testing, and human leukocyte antigen (HLA) typing. The testing is utilized by various end users, including hospitals, fertility centers, diagnostic centers, research institutions, and academic laboratories.

The preimplantation genetic testing market research report is one of a series of new reports that provides preimplantation genetic testing market statistics, including preimplantation genetic testing industry global market size, regional shares, competitors with a preimplantation genetic testing market share, detailed preimplantation genetic testing market segments, market trends and opportunities, and any further data you may need to thrive in the preimplantation genetic testing industry. This preimplantation genetic testing market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The preimplantation genetic testing (PGT) market consists of revenues earned by entities by providing services such as data analysis tools, genetic counseling, cloud-based platforms, and embryo selection algorithms. The market value includes the value of related goods sold by the service provider or included within the service offering. The preimplantation genetic testing (PGT) market also includes sales of genetic testing (PGT) kits, next-generation sequencers, and polymerase chain reaction (PCR) machines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.